Norgine B.V., a European specialist pharmaceutical company, announced that it is supporting the March 2016 European Colorectal Cancer awareness campaign. Colorectal cancer is the second most common cause of cancer-related mortality in the world1, with nearly 1.4 million new cases diagnosed worldwide and 412,000 people in Europe.

As a leader in bowel cleansing and colonoscopy, Norgine has been collaborating with key European patient organisations in order to increase the detection of colorectal cancer and to help improve patients’ quality of life.

Norgine is a patient centric company and is supporting key organisations such as;   Alianza para la prevención del Cáncer de colon, Spain;  Asociación de pacientes con síndrome de Lynch, Spain;  Beating Bowel Cancer, UK; Bowel Cancer UK; Conseil National Professionnel d’Hépato-Gastroentérologie, France;   Deutschland gegen Darmkrebs, Germany; Dutch Digestive Foundation, The Netherlands;   Felix Burda Foundation, Germany;       Selbsthilfgruppe Darmkrebs, Austria;  Spanish Digestive Society Foundation, Spain;  Stiftung LebensBlicke, Germany; and Stop Darmkanker, Belgium.

Over the years, Norgine has strengthened its colon cancer prevention and detection portfolio to ensure quality in colonoscopy and ultimately enhance health outcomes for patients.

Norigne’s bowel cleansing and colonoscopy portfolio includes Klean-Prep, Moviprep and Endocuff Vision.